Takehito Shukuya
Juntendo University · 241 works · 4,880 citations · h-index 35
Top works
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer
- Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
- Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports
- LBA70 OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)
- Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer
- Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
- Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma
- Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System
- Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
- LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer.
- Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
- Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
- Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease.
- Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies
- Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
- Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
- Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure
- Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer.
- A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients